Hyderabad is where regulated-market manufacturing meets discovery science.
Genome Valley and the wider Telangana cluster produce more regulated-market API and vaccine volume than most countries. We underwrite the companies turning that manufacturing depth into proprietary science.
What we look for in Hyderabad
API, biologics and vaccine platforms with USFDA or EU-GMP inspection history and a credible path from contract volume to owned intellectual property.
Computer-aided and AI-native discovery groups that pair Indian scientific talent with wet-lab validation rather than in-silico claims alone.
Diagnostics and MedTech companies with CDSCO clearance, real reimbursement traction and an export thesis into Gulf and Southeast Asian markets.
How we work locally
We meet founders in Hyderabad in person before term sheets and keep site visits to manufacturing assets a condition of diligence, not a formality.
Post-investment support runs on IST: regulatory sequencing, quality-systems hires, and introductions to Gulf and US commercial partners inside our network.
Frequently asked questions
- Does OceansGled invest directly in Hyderabad-headquartered companies?
- Yes. Fund III is India-focused and Hyderabad is one of our three primary sourcing clusters alongside Mumbai and Chennai.
- What is the minimum cheque size for a Hyderabad company?
- US$10 million, typically at Series A or Series B, with reserved follow-on capital from a capped 25-company portfolio.
- Do you fund pre-clinical discovery in Hyderabad?
- Selectively, and only where preclinical data is independently validated and the team has prior regulated-market execution.